vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Citi Trends Inc (CTRN). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $197.1M, roughly 1.4× Citi Trends Inc). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -3.5%, a 99.8% gap on every dollar of revenue. On growth, Citi Trends Inc posted the faster year-over-year revenue change (10.1% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -4.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.
ACAD vs CTRN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $197.1M |
| Net Profit | $273.6M | $-6.9M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | -3.7% |
| Net Margin | 96.3% | -3.5% |
| Revenue YoY | 9.4% | 10.1% |
| Net Profit YoY | 90.3% | 3.6% |
| EPS (diluted) | $1.61 | $-0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $197.1M | ||
| Q3 25 | $278.6M | $190.8M | ||
| Q2 25 | $264.6M | $201.7M | ||
| Q1 25 | $244.3M | $211.2M | ||
| Q4 24 | $259.6M | $179.1M | ||
| Q3 24 | $250.4M | $176.6M | ||
| Q2 24 | $242.0M | $186.3M | ||
| Q1 24 | $205.8M | $215.2M |
| Q4 25 | $273.6M | $-6.9M | ||
| Q3 25 | $71.8M | $3.8M | ||
| Q2 25 | $26.7M | $871.0K | ||
| Q1 25 | $19.0M | $-14.2M | ||
| Q4 24 | $143.7M | $-7.2M | ||
| Q3 24 | $32.8M | $-18.4M | ||
| Q2 24 | $33.4M | $-3.4M | ||
| Q1 24 | $16.6M | $3.6M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | -3.7% | ||
| Q3 25 | 12.8% | 1.8% | ||
| Q2 25 | 12.2% | 0.2% | ||
| Q1 25 | 7.9% | 0.6% | ||
| Q4 24 | 59.1% | -4.9% | ||
| Q3 24 | 12.6% | -14.1% | ||
| Q2 24 | 12.6% | -3.7% | ||
| Q1 24 | 7.4% | 1.8% |
| Q4 25 | 96.3% | -3.5% | ||
| Q3 25 | 25.8% | 2.0% | ||
| Q2 25 | 10.1% | 0.4% | ||
| Q1 25 | 7.8% | -6.7% | ||
| Q4 24 | 55.4% | -4.0% | ||
| Q3 24 | 13.1% | -10.4% | ||
| Q2 24 | 13.8% | -1.8% | ||
| Q1 24 | 8.0% | 1.7% |
| Q4 25 | $1.61 | $-0.86 | ||
| Q3 25 | $0.42 | $0.46 | ||
| Q2 25 | $0.16 | $0.11 | ||
| Q1 25 | $0.11 | $-1.70 | ||
| Q4 24 | $0.86 | $-0.86 | ||
| Q3 24 | $0.20 | $-2.21 | ||
| Q2 24 | $0.20 | $-0.42 | ||
| Q1 24 | $0.10 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $107.8M |
| Total Assets | $1.6B | $464.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | $1.2B | $107.8M | ||
| Q3 25 | $917.3M | $113.2M | ||
| Q2 25 | $822.4M | $108.6M | ||
| Q1 25 | $765.2M | $113.2M | ||
| Q4 24 | $732.8M | $130.3M | ||
| Q3 24 | $577.2M | $136.6M | ||
| Q2 24 | $516.7M | $154.8M | ||
| Q1 24 | $464.0M | $157.7M |
| Q4 25 | $1.6B | $464.3M | ||
| Q3 25 | $1.3B | $457.4M | ||
| Q2 25 | $1.2B | $437.4M | ||
| Q1 25 | $1.1B | $462.8M | ||
| Q4 24 | $1.2B | $467.1M | ||
| Q3 24 | $976.9M | $506.7M | ||
| Q2 24 | $914.1M | $484.1M | ||
| Q1 24 | $855.1M | $518.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $8.6M |
| Free Cash FlowOCF − Capex | — | $767.0K |
| FCF MarginFCF / Revenue | — | 0.4% |
| Capex IntensityCapex / Revenue | — | 4.0% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $11.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $8.6M | ||
| Q3 25 | $74.3M | $3.9M | ||
| Q2 25 | $64.0M | $-11.0M | ||
| Q1 25 | $20.3M | $28.5M | ||
| Q4 24 | $40.4M | $-18.4M | ||
| Q3 24 | $63.2M | $5.6M | ||
| Q2 24 | $25.0M | $-19.6M | ||
| Q1 24 | $29.1M | $23.3M |
| Q4 25 | — | $767.0K | ||
| Q3 25 | $73.9M | $-1.7M | ||
| Q2 25 | — | $-13.1M | ||
| Q1 25 | — | $26.0M | ||
| Q4 24 | — | $-20.4M | ||
| Q3 24 | $63.2M | $1.7M | ||
| Q2 24 | — | $-21.2M | ||
| Q1 24 | — | $20.0M |
| Q4 25 | — | 0.4% | ||
| Q3 25 | 26.5% | -0.9% | ||
| Q2 25 | — | -6.5% | ||
| Q1 25 | — | 12.3% | ||
| Q4 24 | — | -11.4% | ||
| Q3 24 | 25.2% | 0.9% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | 9.3% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | 0.1% | 2.9% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 1.5% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 1.01× | ||
| Q2 25 | 2.40× | -12.59× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 1.76× | 6.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CTRN
Segment breakdown not available.
